JP2011514337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514337A5 JP2011514337A5 JP2010547860A JP2010547860A JP2011514337A5 JP 2011514337 A5 JP2011514337 A5 JP 2011514337A5 JP 2010547860 A JP2010547860 A JP 2010547860A JP 2010547860 A JP2010547860 A JP 2010547860A JP 2011514337 A5 JP2011514337 A5 JP 2011514337A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vlp
- powder
- sugar glass
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 37
- 239000000843 powder Substances 0.000 claims 22
- 239000011521 glass Substances 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 238000000034 method Methods 0.000 claims 10
- 150000002016 disaccharides Chemical class 0.000 claims 8
- 150000002772 monosaccharides Chemical class 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 7
- -1 Ma N'nitoru Natural products 0.000 claims 6
- 206010022000 influenza Diseases 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 5
- 239000002245 particle Substances 0.000 claims 5
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims 4
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 4
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 4
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims 4
- 229930006000 Sucrose Natural products 0.000 claims 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 4
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 4
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 4
- 239000003125 aqueous solvent Substances 0.000 claims 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims 4
- 229930182830 galactose Natural products 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 4
- 239000008101 lactose Substances 0.000 claims 4
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims 4
- 229960000511 lactulose Drugs 0.000 claims 4
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims 4
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000000600 sorbitol Substances 0.000 claims 4
- 239000005720 sucrose Substances 0.000 claims 4
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 claims 4
- 238000001802 infusion Methods 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 239000001087 glyceryl triacetate Substances 0.000 claims 1
- 235000013773 glyceryl triacetate Nutrition 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940074928 isopropyl myristate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 229940057917 medium chain triglycerides Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 229960002622 triacetin Drugs 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3124308P | 2008-02-25 | 2008-02-25 | |
| PCT/US2009/035122 WO2009108689A1 (en) | 2008-02-25 | 2009-02-25 | Sugar glassified virus like particles (vlps) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011514337A JP2011514337A (ja) | 2011-05-06 |
| JP2011514337A5 true JP2011514337A5 (https=) | 2012-04-05 |
Family
ID=41016454
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547860A Pending JP2011514337A (ja) | 2008-02-25 | 2009-02-25 | 糖ガラス化ウィルス様粒子（ｖｌｐ） |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP2254554A1 (https=) |
| JP (1) | JP2011514337A (https=) |
| CN (1) | CN102014873A (https=) |
| BR (1) | BRPI0908861A2 (https=) |
| CA (1) | CA2716546A1 (https=) |
| MX (1) | MX2010009351A (https=) |
| RU (1) | RU2010139478A (https=) |
| WO (1) | WO2009108689A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11446374B2 (en) | 2008-12-09 | 2022-09-20 | Novavax, Inc. | Modified RSV F proteins and methods of their use |
| JP5813513B2 (ja) | 2008-12-09 | 2015-11-17 | ノババックス，インコーポレイテッド | 修飾ｒｓｖｆタンパク質及びその使用方法 |
| EP2519539A4 (en) * | 2009-12-28 | 2013-11-13 | Ligocyte Pharmaceuticals Inc | METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES |
| GB201002419D0 (en) * | 2010-02-12 | 2010-03-31 | Isis Innovation | Stable live vaccine formulations |
| MX349294B (es) * | 2010-12-02 | 2017-07-21 | Oncolytics Biotech Inc | Formulaciones virales liofilizadas. |
| AU2011336413B2 (en) | 2010-12-02 | 2015-01-22 | Oncolytics Biotech Inc. | Liquid viral formulations |
| US20140127260A1 (en) * | 2011-06-24 | 2014-05-08 | Ramesh V. Chintala | Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same |
| US20130122032A1 (en) * | 2011-09-30 | 2013-05-16 | Gale Smith | Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus |
| US20130089638A1 (en) * | 2011-10-11 | 2013-04-11 | Mead Johnson Nutrition Company | Compositions Comprising Maltotriose And Methods Of Using Same To Inhibit Damage Caused By Dehydration Processes |
| RU2720808C2 (ru) | 2013-09-03 | 2020-05-13 | Джорджия Тек Рисёч Корпорейшн | Термостабильные препараты вакцин и микроиглы |
| AU2014364930B2 (en) | 2013-12-16 | 2017-06-15 | Massachusetts Institute Of Technology | Micromolded or 3-D printed pulsatile release vaccine formulations |
| MX2016007786A (es) | 2013-12-16 | 2017-03-03 | Massachusetts Inst Technology | Formulaciones de sal de micronutrientes fortificadas. |
| IL310015B2 (en) * | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| US11273127B2 (en) | 2014-05-06 | 2022-03-15 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for thermally stable multi-targeted antigens |
| EP3139952A1 (en) * | 2014-05-06 | 2017-03-15 | The Regents of the University of Colorado, a body corporate | Compositions, methods and uses for thermally stable human papillomavirus formulations |
| EP4494650A3 (en) | 2015-09-03 | 2025-03-26 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| WO2017041083A1 (en) * | 2015-09-04 | 2017-03-09 | Inventprise, Llc | Vlp stabilized vaccine compositions |
| WO2019023196A1 (en) | 2017-07-24 | 2019-01-31 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE |
| EP3768308A4 (en) | 2018-03-19 | 2022-01-26 | Novavax, Inc. | MULTIVALENT INFLUENZA NANOPARTICLE VACCINES |
| EP3976092A1 (en) * | 2019-05-25 | 2022-04-06 | Infectious Disease Research Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
| JP7776145B2 (ja) | 2020-05-13 | 2025-11-26 | マサチューセッツ インスティテュート オブ テクノロジー | ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用 |
| CN115350281B (zh) * | 2022-09-20 | 2026-01-02 | 华派生物技术(集团)股份有限公司 | 一种病毒样颗粒疫苗冻干保护剂及其制备方法 |
| WO2025058011A1 (ja) * | 2023-09-13 | 2025-03-20 | 国立大学法人大阪大学 | 経鼻投与用組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| GB9705588D0 (en) * | 1997-03-18 | 1997-05-07 | Anglia Research Foundation | Stable particle in liquid formulations |
| CN1777411B (zh) * | 2003-02-24 | 2013-01-02 | 药品生产公司 | 经粘膜药物递送系统 |
| GB0409795D0 (en) * | 2004-04-30 | 2004-06-09 | Glaxosmithkline Biolog Sa | Drying method |
| US7871632B2 (en) * | 2004-07-12 | 2011-01-18 | Adventrx Pharmaceuticals, Inc. | Compositions for delivering highly water soluble drugs |
| GB0502661D0 (en) * | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| TW200640492A (en) * | 2005-02-21 | 2006-12-01 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
-
2009
- 2009-02-25 JP JP2010547860A patent/JP2011514337A/ja active Pending
- 2009-02-25 CA CA2716546A patent/CA2716546A1/en not_active Abandoned
- 2009-02-25 WO PCT/US2009/035122 patent/WO2009108689A1/en not_active Ceased
- 2009-02-25 EP EP09713904A patent/EP2254554A1/en not_active Withdrawn
- 2009-02-25 CN CN2009801146099A patent/CN102014873A/zh active Pending
- 2009-02-25 BR BRPI0908861A patent/BRPI0908861A2/pt not_active IP Right Cessation
- 2009-02-25 RU RU2010139478/15A patent/RU2010139478A/ru not_active Application Discontinuation
- 2009-02-25 MX MX2010009351A patent/MX2010009351A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011514337A5 (https=) | ||
| RU2010139478A (ru) | Соединенные с сахарным стеклом вирусоподобные частицы (vlp) | |
| EP2647387B1 (en) | Vaccine Composition | |
| JP2013515015A5 (https=) | ||
| US20060233830A1 (en) | Vaccines | |
| JP2010539172A5 (https=) | ||
| JP2011037876A5 (https=) | ||
| CA2383105A1 (en) | Intranasal influenza virus vaccine | |
| ZA200403848B (en) | Pharmaceutical compositions in particulate form | |
| US8216588B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP6041361B2 (ja) | 生物学的製品、特にはワクチンの真空保存 | |
| JP2013544288A5 (https=) | ||
| US20120045479A1 (en) | Dry Powder Formulations, Vaccines and Methods | |
| IS7671A (is) | Ónæmisvaka samsetningar | |
| US20120219590A1 (en) | Formulations useful for spray drying vaccines | |
| GB2395900A (en) | Therapeutic composition for respiratory delivery | |
| US20110150927A1 (en) | Stabilisation of Viral Microparticles | |
| CN102614212B (zh) | 小儿利巴韦林组合物冻干口腔崩解片及其制备方法 | |
| Payton et al. | Lyophilized vaccine development | |
| CN108289947A (zh) | 流感疫苗干燥制剂和流感疫苗干燥制剂的制造方法 | |
| JP2009517386A5 (https=) | ||
| US20140356396A1 (en) | Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures | |
| US20230115214A1 (en) | Dry powder compositions of oil-in-water (o/w) emulsion adjuvanted vaccines | |
| Beugeling | Biodegradable implants for the biphasic pulsatile delivery of antigens: Toward single-injection vaccines | |
| EP4699604A1 (en) | Inhaled adenovirus vector vaccine, preparation method therefor and use thereof |